Though previous studies have evaluated efficacy of glutaminase inhibitors in cancers such as triple negative breast cancer [28], acute myeloid leukemia [35] and pancreatic cancer [36], glutamine dependency in NF1 associated malignancies has not been studied before. Here, GLS is linked to triple-negative breast carcinoma.